Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Radius Health Announces Scientific Presentations at 2019 San Antonio Breast Cancer Symposium (SABCS)
WALTHAM, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced its scientific presentations on elacestrant and RAD140 at the...
-
BOSTON, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flywire, a global payment solution provider, has been selected as a winner in this year’s Fierce Innovation Awards – Healthcare Edition, a peer- reviewed...
-
Thorofare, New Jersey, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive...
-
BEIJING, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, hemp...
-
SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the...
-
DALLAS, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced two new engineering awards with a combined value over...
-
ANCHORAGE, Alaska, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ: NRIM) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.33 per share....
-
GERMANTOWN, Md., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO...
-
Xenon’s Epilepsy Programs Continue to Advance Including Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans for Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in...
-
ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections...